Audentes Therapeutics, Inc. Research and Development Expense
Audentes Therapeutics, Inc. reported Research and Development Expense of $37.64 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2019-11-07
- Audentes Therapeutics, Inc. research and development expense for the quarter ending 2019-09-30 was $37.64M, a 25.80% increase year-over-year.
- Audentes Therapeutics, Inc. research and development expense for the quarter ending 2019-06-30 was $37.30M, a 41.56% increase year-over-year.
- Audentes Therapeutics, Inc. research and development expense for the quarter ending 2019-03-31 was $39.84M, a 100.28% increase year-over-year.
- Audentes Therapeutics, Inc. research and development expense for the quarter ending 2018-12-31 was $28.21M, a 30.19% increase year-over-year.
- Audentes Therapeutics, Inc. research and development expense for fiscal 2018 was $104.37M, a 37.51% increase from fiscal 2017.
- Audentes Therapeutics, Inc. research and development expense for fiscal 2017 was $75.90M, a 55.63% increase from fiscal 2016.
- Audentes Therapeutics, Inc. research and development expense for fiscal 2016 was $48.77M, a 141.02% increase from fiscal 2015.
- Audentes Therapeutics, Inc. research and development expense for fiscal 2015 was $20.23M, a 118.05% increase from fiscal 2014.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2019-09-30 | $37.64M 10-Q · filed 2019-11-07 | $74.94M derived: sum of 2 quarters · filed 2019-11-07 | $114.77M 10-Q · filed 2019-11-07 | $142.99M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2019-06-30 | $37.30M 10-Q · filed 2019-08-07 | $77.14M 10-Q · filed 2019-08-07 | $105.35M derived: sum of 3 quarters · filed 2019-08-07 | $135.27M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2019-03-31 | $39.84M 10-Q · filed 2019-05-08 | $68.05M derived: sum of 2 quarters · filed 2019-05-08 | $97.97M derived: sum of 3 quarters · filed 2019-11-07 | $124.32M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-12-31 | $28.21M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $58.13M derived: sum of 2 quarters · filed 2019-11-07 | $84.48M derived: sum of 3 quarters · filed 2019-11-07 | $104.37M 10-K · filed 2019-03-01 | |
| 2018-09-30 | $29.92M 10-Q · filed 2019-11-07 | $56.27M derived: sum of 2 quarters · filed 2019-11-07 | $76.16M 10-Q · filed 2019-11-07 | $97.83M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | $26.35M 10-Q · filed 2019-08-07 | $46.24M 10-Q · filed 2019-08-07 | $67.91M derived: sum of 3 quarters · filed 2019-08-07 | $88.78M derived: sum of 4 quarters · filed 2019-08-07 | |
| 2018-03-31 | $19.89M 10-Q · filed 2019-05-08 | $41.56M derived: sum of 2 quarters · filed 2019-05-08 | $62.43M derived: sum of 3 quarters · filed 2019-05-08 | $81.21M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | $21.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $42.54M derived: sum of 2 quarters · filed 2019-03-01 | $61.31M derived: sum of 3 quarters · filed 2019-03-01 | $75.90M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $20.87M 10-Q · filed 2018-11-07 | $39.64M derived: sum of 2 quarters · filed 2018-11-07 | $54.23M 10-Q · filed 2018-11-07 | $70.83M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | $18.78M 10-Q · filed 2018-08-07 | $33.36M 10-Q · filed 2018-08-07 | $49.96M derived: sum of 3 quarters · filed 2019-03-01 | $62.49M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-03-31 | $14.59M 10-Q · filed 2018-05-10 | $31.19M derived: sum of 2 quarters · filed 2019-03-01 | $43.72M derived: sum of 3 quarters · filed 2019-03-01 | $55.45M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2016-12-31 | $16.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $29.13M derived: sum of 2 quarters · filed 2019-03-01 | $40.86M derived: sum of 3 quarters · filed 2019-03-01 | $48.77M 10-K · filed 2019-03-01 | |
| 2016-09-30 | $12.53M 10-Q · filed 2017-11-14 | $24.27M derived: sum of 2 quarters · filed 2017-11-14 | $32.17M 10-Q · filed 2017-11-14 | $40.07M derived: sum of 4 quarters · filed 2018-03-09 | |
| 2016-06-30 | $11.73M 10-Q · filed 2017-08-10 | $11.73M 10-Q · filed 2016-09-01 | $19.64M 10-Q · filed 2017-08-10 | $27.54M derived: sum of 3 quarters · filed 2018-03-09 | $32.84M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | $7.91M 10-Q · filed 2017-05-11 | $15.81M derived: sum of 2 quarters · filed 2018-03-09 | $21.10M derived: sum of 3 quarters · filed 2018-03-09 | $25.06M derived: sum of 4 quarters · filed 2018-03-09 | |
| 2015-12-31 | $7.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $13.20M derived: sum of 2 quarters · filed 2018-03-09 | $17.16M derived: sum of 3 quarters · filed 2018-03-09 | $20.23M 10-K · filed 2018-03-09 | |
| 2015-09-30 | $5.29M 10-Q · filed 2016-11-10 | $9.26M derived: sum of 2 quarters · filed 2016-11-10 | $12.34M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $3.96M 10-Q · filed 2016-09-01 | $7.04M 10-Q · filed 2016-09-01 | |||
| 2014-12-31 | $9.28M 10-K · filed 2017-03-13 |